GAD1 and Anxiety: No differences were observed in depressive or anxiety symptoms at baseline (EPDS: 15.85 vs. 15.72, <i>p</i> = 0.546; GAD-7: 11.70 vs. 11.96, <i>p</i> = 0.3670) or at 3 months (EPDS: 9.09 vs. 9.09, <i>p</i> = 0.980; GAD-7: 6.42 vs. 6.38, <i>p</i> = 0.907).<h4>Conclusions</h4>Engagement, efficacy, and experience were comparable across pandemic phases, highlighting the feasibility of telemedicine-based adaptations in the midst of public health crises.